Posts

Merck’s Lipfendra becomes world’s first oral PCSK9 treatment approved by FDA

on

Merck Unveils Phase 3 Data: Oral PCSK9 Inhibitor Enlicitide Outperforms Rivals in Cholesterol Reduction

on

Merck Touts Strong Comparator Data for Enlicitide Decanoate, Oral PCSK9 Inhibitor Reducing LDL-C by Up to 60% in Phase 3 Trials

on

Merck Reports Pivotal PCSK9 Pill Data in Race to Beat AstraZeneca to Market

on

Amgen’s Repatha Reduces First-Time Cardiovascular Events by 25% in Major Clinical Trial

on

Amgen Builds Case for Repatha to Prevent Heart Disease With Landmark Late-Stage Data

on

Amgen's Repatha Cholesterol-Lowering Shot Poised for Sales Boost After Landmark CV Prevention Trial Success

on

Merck’s Oral PCSK9 Inhibitor Enlicitide Decanoate Achieves Third Consecutive Phase 3 Success

on

Merck's Oral PCSK9 Inhibitor Enlicitide Significantly Reduces LDL Cholesterol in Phase 3 Trials

on

AstraZeneca's oral PCSK9 inhibitor halves cholesterol in phase 2 trial

on